Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
http://www.priceseries.com/trade/FLKS-Flex-Pharma-Inc-stock-gains-91-percent-a-Trade-Record-by-priceSeries-2021020320210218.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments